BACE-1 Antibody (137612)

Western blot shows lysates of human brain (Alzheimer's disease hippocampus) tissue. PVDF Membrane was probed with 2 µg/mL of Mouse Anti-Human/Mouse BACE‑1 Ectodomain Monoclonal Antibody (Catalog # MAB931) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Specific bands were detected for BACE‑1 at approximately 60 and 70 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

• Reactivity: Hu, Mu
• Applications: WB, IHC, CyTOF-ready, Flow
• Clone: 137612
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH
• Suitable Sample Type: 23038

BACE-1 Antibody (137612) Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human BACE-1
  Thr22-Tyr460
  Accession # P56817
• Specificity: Detects human and mouse BACE-1 in direct ELISAs and human BACE-1 in Western blots. In Western blots, no cross-reactivity with recombinant human (rh) BACE-2, recombinant mouse (rm) BACE-2, rhADAM8, rmADAM9, rmADAM10, rhADAM15, or rhTACE is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: BACE1
• Purity: Protein A or G purified from hybridoma culture supernatant
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Western Blot 2 ug/mL
  • Immunohistochemistry 8-25 ug/mL
  • CyTOF-ready
  • Intracellular Staining by Flow Cytometry 2.5 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Protein A or G purified from hybridoma culture supernatant
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for BACE-1 Antibody (137612)

• APP beta-secretase
• ASP2
• Aspartyl protease 2
• BACE1
• BACE-1
• BACEAsp 2
• beta-secretase 1 precursor variant 1
• beta-secretase 1
• beta-site amyloid beta A4 precursor protein-cleaving enzyme
• Beta-site amyloid precursor protein cleaving enzyme 1
• Beta-site APP cleaving enzyme 1
• beta-site APP-cleaving enzyme 1
• beta-site APP-cleaving enzyme
• EC 3.4.23
• EC 3.4.23.46
• FLJ90568
• HSPC104
• KIAA1149
• memapsin-2
• Membrane-associated aspartic protease 2
• transmembrane aspartic proteinase Asp2

Background

BACE-1 (beta‑site APP cleaving enzyme-1) is an aspartic protease and an integral membrane protein (1, 2). It is the major beta secretase, and together with the gamma  secretase, is responsible for generating the amyloid beta peptide (A beta ) from the amyloid precursor protein (APP) (3, 4). Because A beta is a major component of amyloid plaques, BACE-1 has been implicated in the onset and/or progression of Alzheimer's disease. High levels of BACE-1 activity are sufficient to elicit neurodegeneration and neurological decline in vivo, indicating that inhibiting BACE-1 may block not only A beta -dependent but also A beta -independent pathogenic mechanisms (5). In addition to APP, BACE-1 also cleaves APP-like proteins 1 and 2, the cell adhesion protein P-selectin glycoprotein ligand-1 and beta -galactoside alpha 2,6-sialyltransferase, implying that BACE-1 may have additional functions involving the ectodomain shedding of membrane proteins (6‑8).

1. Vassar, R. et al. (1999) Science 286:735.
2. Yan, R. et al. (1999) Nature 402:533.
3. Cai, H. et al. (2001) Nature Neurosci. 4:233.
4. Roberds, S.L. et al. (2001) Human Mol. Genet. 97:1317.
5. Rockenstein, E. et al. (2005) J. Biol. Chem. 280:32957.
6. Li, Q and T.C. Sudhof (2004) J. Biol. Chem. 279:10542.
7. Lichtenthaler, S.F. et al. (2003) J. Biol. Chem. 278:48713.
8. Kitazynem, S. et al. (2005) J. Biol. Chem. 280:8589.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for BACE-1 Antibody (MAB931)(5)

Publications using MAB931

• A Mendsaikha, I Tooyama, JP Bellier, GE Serrano, LI Sue, LF Lue, TG Beach, DG Walker Characterization of lysosomal proteins Progranulin and Prosaposin and their interactions in Alzheimer's disease and aged brains: increased levels correlate with neuropathology Acta Neuropathol Commun, 2019;7(1):215. 2019 [PMID: 31864418] (Western Blot, Human)
• Schnoder L, Hao W, Qin Y, Liu S, Tomic I, Liu X, Fassbender K, Liu Y Deficiency of Neuronal p38alpha MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1. J Biol Chem, 2015;291(5):2067-79. 2015 [PMID: 26663083] (Western Blot, Human)
• Wang Y, Thinakaran G, Kar S Overexpression of the IGF-II/M6P receptor in mouse fibroblast cell lines differentially alters expression profiles of genes involved in Alzheimer's disease-related pathology. PLoS ONE, 2014;9(5):e98057. 2014 [PMID: 24846272] (Western Blot, Mouse)
• Cheng X, He P, Lee T, Yao H, Li R, Shen Y High activities of BACE1 in brains with mild cognitive impairment. Am J Pathol, 2014;184(1):141-7. 2014 [PMID: 24332014] (ELISA Development, Human)
• Ahmed RR, Holler CJ, Webb RL BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J. Neurochem., 2010;112(4):1045-53. 2010 [PMID: 19968762] (ELISA Development, Human)

Bioinformatics

• Gene Symbol: BACE1
• Uniprot:
  • P56817()